TP53 mutations in human cancers: origins, consequences, and clinical use.

Cited by (1,002)

Items 201–300 of 1,002

1. Degradation of mutant p53H175 protein by Zn(II) through autophagy
   Alessia Garufi, D. Pucci, Valerio D’Orazi, Mara Cirone, Gianluca Bossi, Maria Laura Avantaggiati, Gabriella D’Orazi · 2014 · Cell Death and Disease
2. Do Mutations Turn p53 into an Oncogene?
   Consuelo Pitolli, Ying Wang, Mara Mancini, Yufang Shi, Gerry Melino, Ivano Amelio · 2019 · International Journal of Molecular Sciences
3. Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network
   Haupt, Sue, Caramia, Franco, Herschtal, Alan, Soussi, Thierry, Lozano, Guillermina, Chen, Hu, Liang, Han, Speed, Terence P., Haupt, Ygal · 2019 · Nature Communications
4. Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
   Evrim Gurpinar, Karen H. Vousden · 2015 · Trends in Cell Biology
5. Oncometabolites drive tumorigenesis by enhancing protein acylation: from chromosomal remodelling to nonhistone modification
   Yidian Fu, Jie Yu, Fang Li, Shengfang Ge · 2022 · Journal of Experimental & Clinical Cancer Research
6. Graph Neural Networks in Modern AI-Aided Drug Discovery
   Odin Zhang, Haitao Lin, Xujun Zhang, Xiaorui Wang, Zhenxing Wu, Qing Ye, Weibo Zhao, Jike Wang, Kejun Ying, Yu Kang et al. · 2025 · Chemical Reviews
7. Capsaicin Mediates Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells via Stabilizing and Activating p53
   Jun-Zhe Jin, Guofu Lin, Hong Huang, Dong Ming Xu, Hao Yu, Xu Ma, Lisi Zhu, Dongyan Ma, Honglei Jiang · 2014 · International Journal of Biological Sciences
8. Deep learning-based classification and mutation prediction from histopathological images of hepatocellular carcinoma
   Liao, Haotian, Long, Yuxi, Han, Ruijiang, Wang, Wei, Xu, Lin, Liao, Mingheng, Zhang, Zhen, Wu, Zhenru, Shang, Xuequn, Li, Xuefeng et al. · 2020 · Clinical and Translational Medicine
9. The GRHL2/ZEB Feedback Loop-A Key Axis in the Regulation of EMT in Breast Cancer
   Steven M. Mooney, Vida Talebian, Mohit Kumar Jolly, Dongya Jia, Monica Gromala, Herbert Levine, Brendan J. McConkey · 2017 · Journal of Cellular Biochemistry
10. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy
    Jodi A. McKenzie, Rina M. Mbofung, Shruti Malu, Min Zhang, Emily L. Ashkin, Seram Devi, Leila J. Williams, Trang N. Tieu, Weiyi Peng, Sunila Pradeep et al. · 2017 · JNCI Journal of the National Cancer Institute
11. Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer
    Fangyuan Zhou, Haiyang Gao, Luorui Shang, Jinxiao Li, Mengqi Zhang, Shuhan Wang, Runze Li, Lin Ye, Shenglan Yang · 2023 · Journal of Experimental & Clinical Cancer Research
12. Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells
    Guen Tae Kim, Se Hee Lee, Young Min Kim · 2013 · Journal of Cancer Prevention
13. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1
    Loizou, Evangelia, Banito, Ana, Livshits, Geulah, Ho, Yu-Jui, Koche, Richard P., Sánchez-Rivera, Francisco J., Mayle, Allison, Chen, Chi-Chao, Kinalis, Savvas, Bagger, Frederik O. et al. · 2019 · Cancer Discovery
14. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
    Bernard Leroy, Mandy L. Ballinger, Fanny Baran‐Marszak, Gareth L. Bond, Antony W. Braithwaite, Nicole Concin, Lawrence A. Donehower, Wafik S. El‐Deiry, Pierre Fenaux, Gianluca Gaïdano et al. · 2017 · Cancer Research
15. TP53 mutations in cancer: Molecular features and therapeutic opportunities (Review)
    Maria Lina Tornesello · 2024 · International Journal of Molecular Medicine
16. P53 functional abnormality in mesenchymal stem cells promotes osteosarcoma development
    Tania Velletri, N Xie, Ying Wang, Yin Huang, Qinqin Yang, Xuetao Chen, Qing Chen, Peishun Shou, Yaokai Gan, Guoliang Cao et al. · 2016 · Cell Death and Disease
17. Reciprocal Crosstalk Between YAP1/Hippo Pathway and the p53 Family Proteins: Mechanisms and Outcomes in Cancer
    Nitin Raj, Rakesh Bam · 2019 · Frontiers in Cell and Developmental Biology
18. Genome-wide profiling reveals stimulus-specific functions of p53 during differentiation and DNA damage of human embryonic stem cells
    Kadir Caner Akdemir, Abhinav K. Jain, Kendra L. Allton, Bruce J. Aronow, Xueping Xu, Austin J. Cooney, Wěi Li, Michelle Craig Barton · 2013 · Nucleic Acids Research
19. Coordinated Conformational Processing of the Tumor Suppressor Protein p53 by the Hsp70 and Hsp90 Chaperone Machineries
    Vinay Dahiya, Ganesh N. Agam, Jannis Lawatscheck, Daniel Andreas Rutz, Don C. Lamb, Johannes Büchner · 2019 · Molecular Cell
20. The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges
    Susan M. Bigby, Lois Eva, Kah Leng Fong, Ronald W. Jones · 2016 · International Journal of Gynecological Pathology
21. Telomeres: Implications for Cancer Development
    Aina Bernal, Laura Tusell · 2018 · International Journal of Molecular Sciences
22. Synthetic Metallochaperone ZMC1 Rescues Mutant p53 Conformation by Transporting Zinc into Cells as an Ionophore
    Adam R. Blanden, Xin Yu, Aaron J. Wolfe, John Gilleran, David J. Augeri, Ryan S. O’Dell, Eric C. Olson, S. David Kimball, Thomas J. Emge, Liviu Movileanu et al. · 2015 · Molecular Pharmacology
23. Oral squamous cell carcinoma: Key clinical questions, biomarker discovery, and the role of proteomics
    Uzma Urooj Malik, Shamshad Zarina, Stephen R. Pennington · 2015 · Archives of Oral Biology
24. Transcriptional Regulation of Energy Metabolism in Cancer Cells
    Sara Rodríguez‐Enríquez, Álvaro Marín‐Hernández, Juan Carlos Gallardo‐Pérez, Silvia Cecilia Pacheco-Velázquez, Javier Belmont-Díaz, Diana Xochiquetzal Robledo‐Cadena, Jorge Luis Vargas-Navarro, Norma Angélica Corona de la Peña, Emma Saavedra, Rafael Moreno‐Sánchez · 2019 · Cells
25. A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer
    Vetriselvan Subramaniyan, Shivkanya Fuloria, Gaurav Gupta, Darnal Hari Kumar, Mahendran Sekar, Kathiresan V. Sathasivam, Kalvatala Sudhakar, Khalid Saad Alharbi, Waleed Hassan Almalki, Obaid Afzal et al. · 2021 · Chemico-Biological Interactions
26. Base changes in tumour DNA have the power to reveal the causes and evolution of cancer
    M. Hollstein, L. Alexandrov, Cp Wild, M. Ardin, J. Zavadil · 2016 · Oncogene
27. Clinical significance of p53 protein expression and TP53 variation status in colorectal cancer
    Kyoung Min Kim, Ae-Ri Ahn, Ho Sung Park, Kyu Yun Jang, Woo Sung Moon, Myoung Jae Kang, Gi Won Ha, Min Ro Lee, Myoung Ja Chung · 2022 · BMC Cancer
28. Mutation Screening of the TP53 Gene by Temporal Temperature Gel Electrophoresis (TTGE)
    Thérese Sørlie, Hilde Johnsen, Phuong Vu, Guro Elisabeth Lind, Ragnhild A. Lothe, Anne‐Lise Børresen‐Dale · 2014 · Methods in molecular biology
29. Brown Algae Phlorotannins: A Marine Alternative to Break the Oxidative Stress, Inflammation and Cancer Network
    Marcelo D. Catarino, Sónia J. Amarante, Nuno Filipe da Cruz Batista Mateus, Artur M. S. Silva, Susana M. Cardoso · 2021 · Foods
30. Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis
    Tobias Wagner, Peter Brand, Thorsten Heinzel, Oliver Holger Krämer · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
31. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome
    Kelly A. Avery‐Kiejda, Brianna C. Morten, Michelle W. Wong‐Brown, Andrea Mathe, Rodney John Scott · 2013 · Carcinogenesis
32. The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein
    O. Laptenko, David R. Tong, J. Manfredi, C. Prives · 2016 · TIBS -Trends in Biochemical Sciences. Regular ed
33. Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
    Katarina Jovanović, Guillaume Escure, Jordane Demonchy, Alexandre Willaume, Zoé Van de Wyngaert, Méryem-Maud Farhat, Paul Chauvet, Thierry T.F. Facon, Bruno Quesnel, Salomon Manier · 2019 · Frontiers in Oncology
34. Molecularly targeted therapies for p53-mutant cancers
    Dekuang Zhao, William M. Tahaney, Abhijit Mazumdar, Michelle I. Savage, Powel H. Brown · 2017 · Cellular and Molecular Life Sciences
35. Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?
    Prihantono Prihantono, Muhammad Faruk · 2021 · Annals of Medicine and Surgery
36. Role of p53 isoforms and aggregations in cancer
    SeJin Kim, Seong Soo A. An · 2016 · Medicine
37. The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
    Eischen, Christine M., Lozano, Guillermina · 2014 · Human Mutation
38. Extremely High Tp53 Mutation Load in Esophageal Squamous Cell Carcinoma in Golestan Province, Iran
    Behnoush Abedi‐Ardekani, Farin Kamangar, Masoud Sotoudeh, Stéphanie Villar, Farhad Islami, Karim Aghcheli, Dariush Nasrollahzadeh, Noushin Taghavi, Sanford M. Dawsey, Christian C. Abnet et al. · 2011 · PLoS ONE
39. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers
    Vincent M. Chung, Ferdynand J. Kos, Nicola R. Hardwick, Yuan Yuan, Joseph Chao, D. Li, James Ross Waisman, Minzhao Li, Kathryn Zurcher, Paul Henry Frankel et al. · 2018 · Clinical & Translational Oncology
40. Clinical Outcomes of TP53 Mutations in Cancers
    Ana I. Robles, Jin Jen, Curtis C. Harris · 2016 · Cold Spring Harbor Perspectives in Medicine
41. Data-driven unbiased curation of the TP53 tumor suppressor gene mutation database and validation by ultradeep sequencing of human tumors
    Karolina Edlund, Ola Segnestam Larsson, Adam Ameur, Ignas Bunikis, Ulf B Gyllensten, Bernard Leroy, Magnus Sundström, Patrick Micke, Johan Botling, Thierry Soussi · 2012 · Proceedings of the National Academy of Sciences
42. TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions
    Nitin H. Shirole, Debjani Pal, Edward R. Kastenhuber, Şerif Şentürk, Joseph U. Boroda, Paola Pisterzi, Madison Miller, Gustavo Munoz, Marko Anderluh, Marc Ladanyi et al. · 2016 · eLife
43. Mitochondrial dynamics regulating chemoresistance in gynecological cancers
    Bao Kong, Hideaki Tsuyoshi, Makoto Orisaka, Dar‐Bin Shieh, Yoshio Yoshida, Benjamin K. Tsang · 2015 · Annals of the New York Academy of Sciences
44. Emerging roles of the MAGE protein family in stress response pathways
    Rebecca R. Florke Gee, Helen Chen, Anna K. Lee, Christina A. Daly, Benjamin A. Wilander, Klementina Fon Tacer, Patrick Ryan Potts · 2020 · Journal of Biological Chemistry
45. Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations
    W Yuan, Eric W. Stawiski, Vasantharajan Janakiraman, E Chan, Steffen Durinck, Kyle A. Edgar, Noelyn M. Kljavin, Celina Sanchez Rivers, Florian Gnad, Merone Roose‐Girma et al. · 2012 · Oncogene
46. Cutaneous field cancerization: clinical, histopathological and therapeutic aspects
    Luis Antonio Ribeiro Torezan, Cyro Festa Neto · 2013 · Anais Brasileiros de Dermatologia
47. CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
    Florian Bellutti, Anca-Sarmiza Tigan, Sofie Nebenfuehr, Marlies Dolezal, Markus Zojer, Reinhard Grausenburger, Svenja Hartenberger, Sebastian Kollmann, Eszter Doma, Michaela Prchal‐Murphy et al. · 2018 · Cancer Discovery
48. Inactivation and Inducible Oncogenic Mutation of p53 in Gene Targeted Pigs
    Simon Leuchs, Anja Saalfrank, Claudia Merkl, Tatiana Flisikowska, Marlene Edlinger, Marina Durkovic, Nousin Rezaei, Mayuko Kurome, Valeri Zakhartchenko, Barbara Kessler et al. · 2012 · PLoS ONE
49. p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes
    Kyrie Pappas, Jia Xu, Sakellarios Zairis, Lois Resnick‐Silverman, Francesco Abate, Nicole Steinbach, Sait Ozturk, Lao H. Saal, Tao Su, Pamela Cheung et al. · 2017 · Molecular Cancer Research
50. Impact of <i>KRAS</i> and <i>TP53</i> Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With <i>STK11</i>-Mutated Advanced Non–Small-Cell Lung Cancer
    Bange, Erin, Marmarelis, Melina E., Hwang, Wei-Ting, Yang, Yu-Xiao, Thompson, Jeffrey C., Rosenbaum, Jason, Bauml, Joshua M., Ciunci, Christine, Alley, Evan W., Cohen, Roger B. et al. · 2019 · JCO Precision Oncology
51. Macrophage migration inhibitory factor: A key cytokine and therapeutic target in colon cancer
    Alex Nicolas Gordon-Weeks, Su Yin Lim, Arseniy E. Yuzhalin, Keaton Ian Jones, Ruth J. Muschel · 2015 · Cytokine & Growth Factor Reviews
52. Cancer Stemness: p53 at the Wheel
    Dishari Ghatak, Damayanti Das Ghosh, Susanta Roychoudhury · 2021 · Frontiers in Oncology
53. Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11
    Jacqueline E. Noll, Jessie Jeffery, Fares Al‐Ejeh, Raman Kumar, Kum Kum Khanna, David Frederick Callen, Paul Matthew Neilsen · 2011 · Oncogene
54. A fluorescent curcumin-based Zn(II)-complex reactivates mutant (R175H and R273H) p53 in cancer cells
    Alessia Garufi, Daniela Trisciuoglio, Manuela Porru, Carlo Leonetti, Antonella Stoppacciaro, Valerio D’Orazi, Maria Laura Avantaggiati, Alessandra Crispini, Daniela Pucci, Gabriella D’Orazi · 2013 · Journal of Experimental & Clinical Cancer Research
55. Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
    Tay, Ban Qi, Wright, Quentin, Ladwa, Rahul, Perry, Christopher, Leggatt, Graham, Simpson, Fiona, Wells, James W., Panizza, Benedict J., Frazer, Ian H., Cruz, Jazmina L. G. · 2021 · Vaccines
56. LncRNAs in DNA damage response and repair in cancer cells
    Min Su, Heran Wang, Wenxiang Wang, Ying Wang, Linda Ouyang, Pan Chen, Longzheng Xia, Deliang Cao, Qianjin Liao · 2018 · Acta Biochimica et Biophysica Sinica
57. An update on the central nervous system manifestations of Li–Fraumeni syndrome
    Brent A. Orr, Michael R. Clay, Emilia Modolo Pinto, Chimene A. Kesserwan · 2019 · Acta Neuropathologica
58. The Mettl3 epitranscriptomic writer amplifies p53 stress responses
    Nitin Raj, Mengxiong Wang, José Antonio Seoane, Richard L. Zhao, Alyssa M. Kaiser, Nancie A. Moonie, János Demeter, Anthony M. Boutelle, Craig H. Kerr, Abigail S. Mulligan et al. · 2022 · Molecular Cell
59. Control of cell proliferation by memories of mitosis
    Franz Meitinger, Hazrat Belal, Robert Lowell Davis, Mallory B. Martinez, Andrew K. Shiau, Karen Oegema, Arshad B. Desai · 2024 · Science
60. Epithelial ovarian cancer risk: A review of the current genetic landscape
    Nicola Flaum, Emma Jayne Crosbie, Richard John Edmondson, Miriam Jane Smith, D. Gareth Evans · 2019 · Clinical Genetics
61. Analysis of p53 Transactivation Domain Mutants Reveals Acad11 as a Metabolic Target Important for p53 Pro-Survival Function
    Dadi Jiang, Edward L. LaGory, Daniela Kenzelmann Brož, Kathryn T. Bieging-Rolett, Colleen A. Brady, Nichole Link, John Abrams, Amato J. Giaccia, Laura Donatella Attardi · 2015 · Cell Reports
62. Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in Southeast Brazil
    Ana Luíza Seidinger, Maria José Mastellaro, Fernanda Paschoal Fortes, Juliana Godoy Assumpção, Izilda Aparecida Cardinalli, Mônica Aparecida Ganazza, Raul Correa Ribeiro, Sílvia Regina Brandalise, Simone dos Santos Aguiar, José Andrés Yunes · 2010 · Cancer
63. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions
    A. Eldar, H. Rozenberg, Yael Diskin‐Posner, Remo Rohs, Zippora Shakked · 2013 · Nucleic Acids Research
64. SirT3 and p53 Deacetylation in Aging and Cancer
    Ji‐Jun Chen, Aiqin Wang, Qingqi Chen · 2017 · Journal of Cellular Physiology
65. Post-translational modification prediction via prompt-based fine-tuning of a GPT-2 model
    Palistha Shrestha, Jeevan Kandel, Hilal Tayara, K. Chong · 2024 · Nature Communications
66. Development of Synthetic Lethality Anticancer Therapeutics
    Bingliang Fang · 2014 · Journal of Medicinal Chemistry
67. Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53
    DeHart, Caroline J., Chahal, Jasdave S., Flint, S.J., Perlman, David H. · 2014 · Molecular &amp; Cellular Proteomics
68. Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
    Her, Nam-Gu, Oh, Jeong-Woo, Oh, Yun Jeong, Han, Suji, Cho, Hee Jin, Lee, Yeri, Ryu, Gyu Ha, Nam, Do-Hyun · 2018 · Cell Death &amp; Disease
69. Transcriptome analysis of tetraploid cells identifies cyclin D2 as a facilitator of adaptation to genome doubling in the presence of p53
    Tamara Potapova, Christopher W. Seidel, Andrew Box, Giulia Irene Rancati, Rong Li · 2016 · Molecular Biology of the Cell
70. HK3 overexpression associated with epithelial-mesenchymal transition in colorectal cancer
    Elena A. Pudova, Anna V. Kudryavtseva, Maria Fedorova, Andrew R. Zaretsky, Dmitry S. Shcherbo, Elena Lukyanova, Anatoly Popov, А. Ф. Садритдинова, Ivan S. Abramov, Sergey Kharitonov et al. · 2018 · BMC Genomics
71. Explainable drug sensitivity prediction through cancer pathway enrichment
    Yi-Ching Tang, Assaf Gottlieb · 2021 · Scientific Reports
72. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer
    Shengliang Zhang, Lindsey Carlsen, Liz J. Hernández Borrero, Attila A. Seyhan, Xiaobing Tian, Wafik S. El‐Deiry · 2022 · Biomolecules
73. Epigenetic Regulation in Oral Squamous Cell Carcinoma Microenvironment: A Comprehensive Review
    Hassan Mesgari, Samar Esmaelian, Kamyar Nasiri, Shabnam Ghasemzadeh, Parisa Doroudgar, Zahra Payandeh · 2023 · Cancers
74. Genotoxicity of tobacco smoke‐derived aromatic amines and bladder cancer: current state of knowledge and future research directions
    Ahmad Besarati Nia, Stella Tommasi · 2013 · The FASEB Journal
75. Nuclear inclusion bodies of mutant and wild‐type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation
    Frederik De Smet, Mirian Saiz Rubio, Daphne Hompes, Evelyne Naus, Greet De Baets, Tobias Langenberg, Mark S. Hipp, Bert Houben, Filip Claes, Sarah K. Charbonneau et al. · 2016 · The Journal of Pathology
76. The impact of ribosome biogenesis in cancer: from proliferation to metastasis
    Sseu-Pei Hwang, Catherine Denicourt · 2024 · NAR Cancer
77. Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid
    Monica C. Hollstein, Masaaki Moriya, Arthur P. Grollman, Magali Olivier · 2013 · Mutation Research/Reviews in Mutation Research
78. Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
    Krysta Mila Coyle, Jeanette E. Boudreau, Paola Marcato · 2017 · BioMed Research International
79. A systematic study on drug-response associated genes using baseline gene expressions of the cancer cell line encyclopedia
    Liu, Xiaoming, Yang, Jiasheng, Zhang, Yi, Fang, Yun, Wang, Fayou, Wang, Jun, Zheng, Xiaoqi, Yang, Jialiang · 2016 · Scientific Reports
80. Targeting Altered Energy Metabolism in Colorectal Cancer: Oncogenic Reprogramming, the Central Role of the TCA Cycle and Therapeutic Opportunities
    Carina Neitzel, Philipp Demuth, Simon Wittmann, Jörg Fahrer · 2020 · Cancers
81. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer
    Paul Stockhammer, Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu, Hongyu Zhao, Jungmin Choi, Sangyun Tyler Chung, Fangyong Li et al. · 2023 · Journal of Thoracic Oncology
82. Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes
    Laurens G.L. Sand, Károly Szuhai, Pancras C.W. Hogendoorn · 2015 · International Journal of Molecular Sciences
83. Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells
    Jing Zhao, Yixin Lü, Han‐Ming Shen · 2011 · Cancer Letters
84. Patterns of mutations in TP53 mutated AML
    John Sutton Welch · 2018 · Best Practice & Research Clinical Haematology
85. Genetics and Biology of Pancreatic Ductal Adenocarcinoma
    Richard Francis Dunne, Aram F. Hezel · 2015 · Hematology/Oncology Clinics of North America
86. The interplay of UV and cutaneous papillomavirus infection in skin cancer development
    Daniel Hasche, Sonja Stephan, Ilona Braspenning‐Wesch, Julita Mikulec, Martina Niebler, Hermann‐Josef Gröne, Christa Flechtenmacher, Baki Akgũl, Frank Rösl, Sabrina E. Vinzón · 2017 · PLoS Pathogens
87. GADD45A and CDKN1A are involved in apoptosis and cell cycle modulatory effects of viscumTT with further inactivation of the STAT3 pathway
    Susann Kleinsimon, Enya Longmuss, Jana Rolff, Sebastian Jäger, Angelika Eggert, Catharina I. Delebinski, Georg Seifert · 2018 · Scientific Reports
88. Different mutation profiles associated to P53 accumulation in colorectal cancer
    Ignacio López, Ligia P. Oliveira, Paula Tucci, Fernando Álvarez-Valín, Renata A. Coudry, Mónica Marı́n · 2012 · Gene
89. High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort
    Gillian Mitchell, Mandy L. Ballinger, Stephen Q. Wong, Chelsee Hewitt, Paul Andrew James, Mary‐Anne Young, Arcadi Cipponi, Tiffany Wing-Yin Pang, David L. Goode, Alexander Dobrovic et al. · 2013 · PLoS ONE
90. Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells
    Kris G. Hargraves, Lin He, Gary L. Firestone · 2015 · Molecular Carcinogenesis
91. Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness
    David J. Olivos, Lindsey D. Mayo · 2016 · International Journal of Molecular Sciences
92. Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma
    Zhihong Chen, Nishant Soni, Gonzalo Piñero, Bruno Giotti, Devon James Eddins, Katherine E. Lindblad, James Ross, Montserrat Puigdelloses Vallcorba, Tanvi V. Joshi, Angelo Angione et al. · 2023 · Nature Communications
93. Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study
    Balu Kamaraj, Annemie Bogaerts · 2015 · PLoS ONE
94. Hyaluronic acid conjugated β-cyclodextrin-oligoethylenimine star polymer for CD44-targeted gene delivery
    Hui Yan Yin, Feng Zhao, Daohai Zhang, Jun Li · 2015 · International Journal of Pharmaceutics
95. TP53 mutation, mitochondria and cancer
    William M. Kamp, Pingyuan Wang, Paul M. Hwang · 2016 · Current Opinion in Genetics & Development
96. Combined analysis of keratinocyte cancers identifies novel genome-wide loci
    Upekha E. Liyanage, Matthew H. Law, Xikun Han, Jiyuan An, Jue‐Sheng Ong, Puya Gharahkhani, Scott D. Gordon, Rachel Ε. Neale, Catherine M. Olsen, Stuart MacGregor et al. · 2019 · Human Molecular Genetics
97. More targets, more pathways and more clues for mutant p53
    Sonia Garritano, Alberto Inga, Federica Gemignani, Stefano Landi · 2013 · Oncogenesis
98. Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity
    Timo Quante, Benjamin Otto, Marie Brázdová, Iva Kejnovská, Wolfgang Deppert, Genrich V. Tolstonog · 2012 · Cell Cycle
99. Advances in adenovirus-mediated p53 cancer gene therapy
    Hiroshi Tazawa, Shunsuke Kagawa, Toshiyoshi Fujiwara · 2013 · Expert Opinion on Biological Therapy
100. Higher-than-expected population prevalence of potentially pathogenic germlineTP53variants in individuals unselected for cancer history
     Kelvin C. de Andrade, Lisa J. Mirabello, Douglas R. Stewart, Eric Karlins, Roelof Koster, Mingyi Wang, Susan M. Gapstur, Mia M. Gaudet, Neal D. Freedman, Maria Teresa Landi et al. · 2017 · Human Mutation